Ubicación del inventario

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Sujeto a disponibilidad

Documentation

Descargar MSDS

Descargar COA de muestra

Incluye: HPLC, MASS/LC-MS, RMN de 1H, FT-IR, potencia, informe de elucidación estructural (SER) y datos analíticos adicionales según el producto.

5336-53-8N-Nitrosodibenzylamine (NDBzA)

● En Stock

Número de catálogo:	VE006123
N.º CAS:	5336-53-8
Fórmula mol.::	C14H14N2O
Peso mol.::	226.27 g/mol

Solicitar cotización

Añadir a la lista de RFQ

Información adicional sobre el CAS 5336-53-8

Fármaco de origen

Noradrenaline

Nombre IUPAC

N-Nitroso-N-(phenylmethyl)benzenemethanamine

Sinónimos farmacopeicos

N/A

Otros sinónimos

Dibenzylnitrosamine; N,N-Dibenzylnitrosamine; N,N-dibenzylnitrous amide; N-Nitrosodibenzenemethanamine; 1,1-Dibenzyl-2-oxohydrazine

Smile

O=NN(CC1=CC=CC=C1)CC2=CC=CC=C2

InChI

InChI=1S/C14H14N2O/c17-15-16(11-13-7-3-1-4-8-13)12-14-9-5-2-6-10-14/h1-10H,11-12H2

Condición de envío

Ambient Temperature

Characterization Data (Included)

HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, and Structure Elucidation Report (SER).

Datos adicionales de caracterización

QNMR, D2O Exchange, 13C NMR, 13C APT, COSY NMR, NOESY NMR, 15N NMR, HSQC NMR, HMQC NMR, and HMBC NMR. These are available upon request and may be free or subject to additional charges.

Descripción

N-Nitrosodibenzylamine is an N-nitroso derivative of the secondary amine | which is a highly characterized reference material that meets stringent regulatory standards set for nitrosamine compounds | including those set by USP | EMA | JP | and BP. This nitroso standard is essential for a variety of applications | such as analytical method development | method validation (AMV) | and Quality Control (QC) | particularly in the context of API and raw material production. It is suitable for use in both Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). This nitrosamine standard helps establish detection limits | quantify impurity levels | and ensure trace nitroso impurities in pharmaceutical products remain within FDA and EMA safety limits.